

CANCER AUSTRALIA

Entity Resources and Planned Performance



CANCER AUSTRALIA

Section 1: Entity Overview and Resources	290
1.1 Strategic Direction Statement	290
1.2 Entity Resource Statement	291
1.3 Budget Measures	292
Section 2: Outcomes and Planned Performance.....	293
2.1 Budgeted Expenses and Performance for Outcome 1	293
Section 3: Budgeted Financial Statements	298
3.1 Budgeted Financial Statements	298
3.2 Budgeted Financial Statements Tables	299



Section 1: Entity Overview and Resources

1.1 STRATEGIC DIRECTION STATEMENT¹

As the Australian Government's national cancer control agency, Cancer Australia, provides leadership in cancer control across all cancers. Cancer Australia aims to reduce the impact of cancer, address disparities and improve outcomes for people affected by cancer by leading and coordinating national, evidence-based interventions across the continuum of care.

The Australian Government, through Cancer Australia, aims to: provide national leadership in cancer control to improve cancer outcomes; coordinate evidence informed interventions with a range of healthcare providers and groups across the continuum of cancer care; lead the development of sustainable and effective models of cancer care; and provide advice on appropriate cancer care. Cancer Australia oversees dedicated budgets for cancer research, clinical trials and strengthening national data capacity.

In 2018-19, to minimise the impact of cancer, Cancer Australia will:

- continue to implement the *Australian Brain Cancer Mission*, which aims to double survival rates and improve the quality of life of people living with brain cancer over the next ten years;
- continue to implement the *Invest in Medical Research – fighting childhood cancer* program;
- fund research in priority areas through the Priority-driven Collaborative Cancer Research Scheme, including a focus on low survival cancers common among children (0-14 years of age);
- translate evidence to inform the development and implementation of policies and programs in cancer control;
- promote evidence informed clinical practice to health professionals across Australia;
- lead the development of innovative, sustainable, and evidence-based models of cancer care;
- strengthen national data capacity through reporting on cancer stage and treatment for selected cancers;
- provide information for people affected by cancer about their diagnosis and treatment; and
- promote cancer awareness in the community.

The role and functions of Cancer Australia are set out in the *Cancer Australia Act 2006*. Cancer Australia is subject to the *Public Service Act 1999* and the *Auditor-General Act 1997*, and is a non-corporate Commonwealth entity under the *Public Governance, Performance and Accountability Act 2013*.

¹ For more information about the strategic direction of Cancer Australia, refer to the current Corporate Plan, available at: www.canceraustralia.gov.au/about-us/accountability-and-reporting#corporate

1.2 ENTITY RESOURCE STATEMENT

Table 1.1 shows the total funding from all sources available to the entity for its operations and to deliver programs and services on behalf of the Government.

The table summarises how resources will be applied by outcome (Government strategic policy objectives) and by administered (on behalf of the Government or the public) and departmental (for the entity's operations) classification.

For more detailed information on special accounts and special appropriations, refer to *Budget Paper No. 4 – Agency Resourcing*.

Information in this table is presented on a resourcing (i.e. appropriations/cash available) basis, whilst the 'Budgeted expenses by Outcome' tables in Section 2 and the financial statements in Section 3 are presented on an accrual basis.

Table 1.1: Cancer Australia Resource Statement – Budget Estimates for 2018-19 as at Budget May 2018

	2017-18 Estimated actual \$'000	2018-19 Estimate \$'000
DEPARTMENTAL		
Prior year appropriation available	4,419	3,568
Annual appropriations		
Ordinary annual services ^(a)		
Departmental appropriation	11,110	11,088
s74 retained revenue receipts ^(b)	2,265	2,232
Departmental capital budget ^(c)	81	81
Other services ^(d)		
Equity injection	-	-
Total departmental annual appropriations	13,456	13,401
Total departmental resourcing	17,875	16,969
ADMINISTERED		
Prior year appropriation available	30	30
Annual appropriations		
Ordinary annual services ^(a)		
Outcome 1	18,679	19,802
Other services ^(d)		
Administered assets and liabilities	-	-
Total administered annual appropriations	18,679	19,802
Total administered resourcing	18,709	19,832
Total resourcing for Cancer Australia	36,584	36,801
	2017-18	2018-19
Average staffing level (number)	69	71

All figures are GST exclusive.

^(a) Appropriation Bill (No. 1) 2018-19.

^(b) Estimated retained revenue receipts under section 74 of the PGPA Act 2013.

^(c) Departmental Capital Budgets (DCB) are not separately identified in Appropriation Bill (No. 1) and form part of ordinary annual services items. Refer to Table 3.5 for further details. For accounting purposes, this amount has been designated as a 'contribution by owner'.

^(d) Appropriation Bill (No. 2) 2018-19.

1.3 BUDGET MEASURES

This section is not applicable to Cancer Australia.

Section 2: Outcomes and Planned Performance

Government outcomes are the intended results, impacts or consequences of actions by the Government on the Australian community. Commonwealth programs are the primary vehicle by which Government entities achieve the intended results of their outcome statements. Entities are required to identify the programs that contribute to Government outcomes over the Budget and forward years.

Each outcome is described below together with its related programs. The following provides detailed information on expenses for each outcome and program, further broken down by funding source.

Note:

Performance reporting requirements in the Portfolio Budget Statements are part of the enhanced Commonwealth performance framework established by the *Public Governance, Performance and Accountability Act 2013*. It is anticipated that the performance criteria described in Portfolio Budget Statements will be read with broader information provided in an entity's Corporate Plans and Annual Performance Statements – included in Annual Reports – to provide an entity's complete performance story.

Cancer Australia's most recent Corporate Plan is available at:
www.canceraustralia.gov.au/about-us/accountability-and-reporting

Cancer Australia's most recent Annual Performance Statement is available at:
www.canceraustralia.gov.au/about-us/accountability-and-reporting/annual-reports

2.1 BUDGETED EXPENSES AND PERFORMANCE

Outcome 1

Minimised impacts of cancer, including through national leadership in cancer control with targeted research and clinical trials; evidence informed clinical practice; strengthened national data capacity; community and consumer information and support

Program Contributing to Outcome 1

Program 1.1: Improved Cancer Control

Linked Programs

Other Commonwealth entities that contribute to Outcome 1
<p>Department of Health</p> <p>Program 2.4: Preventive Health and Chronic Disease Support</p> <p>The Department of Health has policy responsibility for improving the detection, treatment and survival outcomes for people with cancer. This includes oversight of cancer screening programs, such as the National Bowel Cancer Screening Program and the National Cervical Screening Program.</p>

Budgeted Expenses for Cancer Australia

Table 2.1.1 shows how much the entity intends to spend (on an accrual basis) on achieving the outcome, broken down by program, as well as by administered and departmental funding sources.

Table 2.1.1: Budgeted Expenses for Cancer Australia

	2017-18 Estimated actual \$'000	2018-19 Budget \$'000	2019-20 Forward Year 1 \$'000	2020-21 Forward Year 2 \$'000	2021-22 Forward Year 3 \$'000
Program 1.1: Improved Cancer Control					
Administered expenses					
Ordinary annual services ^(a)	18,679	19,802	19,946	18,381	18,403
Departmental expenses					
Departmental appropriation ^(b)	13,375	13,320	13,168	13,252	11,824
Expenses not requiring appropriation in the Budget year ^(c)	380	403	407	288	258
Operating deficit (surplus)	751	-	-	-	-
Total for Program 1.1	33,185	33,525	33,521	31,921	30,485
Total expenses for Outcome 1	33,185	33,525	33,521	31,921	30,485

	2017-18	2018-19
Average staffing level (number)	69	71

^(a) Appropriation (Bill No. 1) 2018-19.

^(b) Departmental appropriation combines 'Ordinary annual services (Appropriation Bill No. 1)' and 'Revenue from independent sources (s74)'.

^(c) Expenses not requiring appropriation in the Budget year are made up of depreciation expense, amortisation expense, makegood expenses and audit fees.

Movement of Funds

There were no movements of Administered funds between years.

Planned Performance for Cancer Australia

Table 2.1.2 below details the performance criteria for the program associated with Outcome 1. It also summarises how the program is delivered and where 2018-19 Budget measures have materially changed the program.

Table 2.1.2: Performance Criteria for Cancer Australia

Purpose
To minimise the impact of cancer, address disparities, and improve the health outcomes of people affected by cancer in Australia by providing national leadership in cancer control.
Outcome 1
Minimised impacts of cancer, including through national leadership in cancer control with targeted research and clinical trials; evidence informed clinical practice; strengthened national data capacity; community and consumer information and support.
Program 1.1: Improved Cancer Control
Cancer Australia is a specialist agency providing national leadership in cancer control across the cancer continuum of care to minimise the impact of cancer. Cancer Australia guides scientific improvements in cancer prevention, treatment and care; coordinates and liaises between a wide range of stakeholders; makes recommendations to the Australian Government about cancer policies and priorities; assists with the implementation of policies and programs in cancer control; and oversees a dedicated budget for research into cancer.
Delivery
<p>A. Providing leadership in national cancer control and promoting appropriate cancer care</p> <ul style="list-style-type: none"> • Promote evidence informed practice for identified cancers and population groups. • Lead a shared agenda for improvements in cancer outcomes for Aboriginal and Torres Strait Islander peoples in agreed priority areas across the cancer continuum. • Monitor and report national trends in cancer control. <p>B. Funding priority research and strengthening national data capacity</p> <ul style="list-style-type: none"> • Fund brain cancer research through the establishment of a grant program to support new and expanded clinical trials and international collaborations as part of the Australian Brain Cancer Mission. • Partner with non-government organisations to maximise Government investment in priority areas of cancer research, including paediatric cancers of low survival and brain cancer. • Provide funding to support the development of industry independent cancer clinical trials. • Report five-year survival by cancer stage data for the top five incidence adult cancers. <p>C. Promoting cancer awareness and providing information about cancer to the community</p> <ul style="list-style-type: none"> • Engage consumers to inform Cancer Australia’s work. • Provide evidence-based cancer information, resources and data for consumers, health professionals and the community through the Cancer Australia websites, including the National Cancer Control Indicator website, the Children’s cancer website, and social media platforms.



Performance criteria				
A. Providing leadership in national cancer control and promoting appropriate cancer care				
Research is translated into evidence-based information, policy and clinical practice.				
2017-18 Estimated result	2018-19 Target	2019-20 (& beyond) Target		
The Cancer Australia Position Statement on genetic testing for women diagnosed with ovarian cancer translated research into evidence informed recommendations. The Position Statement was endorsed by the relevant colleges, professional associations and consumer organisations.	Evidence is advanced to drive policy change and clinical best practice on the most appropriate interventions across the continuum of cancer care through the publication of research and guidance in specific cancers.	As per 2018-19.		
B. Funding priority research and strengthening national data capacity				
Minimum number of cancer research grants funded by Cancer Australia through the Priority-driven Collaborative Cancer Research Scheme.				
2017-18 Estimated result	2018-19 Target	2019-20 Target	2020-21 Target	2021-22 Target
Target of 7 is on track to be achieved by 30 June 2018.	9	9	9	9
Provide high quality cancer data to inform national cancer control.				
2017-18 Estimated result	2018-19 Target	2019-20 Target	2020-21 Target	2021-22 Target
N/A ²	Collection and reporting of 5-year survival by cancer stage.	Data linkage to inform national cancer control interventions.	Methodology for standardised cancer recurrence developed.	High quality data informs directions of national cancer control.

² This is a new performance criterion for 2018-19, therefore there is no estimated result for 2017-18.

C. Promoting cancer awareness and providing information about cancer to the community				
Number of consumers engaged in Cancer Australia’s work in policy and programs.				
2017-18 Estimated result	2018-19 Target	2019-20 Target	2020-21 Target	2021-22 Target
Target of 70 is on track to be achieved by 30 June 2018.	80	80	80	80
Ensure current evidence informed cancer information, resources and data is continuously available to consumers and health professionals.				
2017-18 Estimated result	2018-19 Target		2019-20 (& beyond) Target	
N/A ³	Regularly review and update the Cancer Australia websites and social media platforms to ensure up-to-date evidence informed cancer information, resources and data is available.		As per 2018-19.	
Material changes to Program 1.1 resulting from the following measures:				
There are no material changes to Program 1.1 resulting from measures.				

³ This is a new performance criterion for 2018-19, therefore there is no estimated result for 2017-18.

Section 3: Budgeted Financial Statements

Section 3 presents budgeted financial statements which provide a comprehensive snapshot of entity finances for the 2018-19 Budget year, including the impact of Budget measures and resourcing on financial statements.

3.1 BUDGETED FINANCIAL STATEMENTS

3.1.1 Differences Between Entity Resourcing and Financial Statements

This section is not applicable to Cancer Australia.

3.1.2 Explanatory Notes and Analysis of Budgeted Financial Statements

Departmental Resources

Comprehensive Income Statement

This statement details budgeted financial results for Cancer Australia in 2018-19.

Cancer Australia has an approved operating loss of \$751,000, net of non-appropriated depreciation and amortisation expenses, in 2017-18.

A break-even position, net of non-appropriated expenses, is anticipated for the 2018-19 Budget and forward years.

The increase in estimated retained revenue receipts aligns with a corresponding increase in supplier and grant expenses from the 2018-19 Budget and forward years.

Balance Sheet

Assets and liabilities are anticipated to remain relatively stable across the forward years. There is an anticipated small decrease in non-financial assets over the forward estimates.

Cash Flow

Cash flows are consistent with income, expenses and asset movements.

Administered Resources

Administered funding for Cancer Australia programs will continue in 2018-19. The level of administered funding across forward years represents Government expenditure on programs delivered to all Australians through Cancer Australia.

3.2 BUDGETED FINANCIAL STATEMENTS TABLES

Table 3.1: Comprehensive Income Statement (showing net cost of services for the period ended 30 June)

	2017-18 Estimated actual	2018-19 Budget	2019-20 Forward estimate	2020-21 Forward estimate	2021-22 Forward estimate
	\$'000	\$'000	\$'000	\$'000	\$'000
EXPENSES					
Employee benefits	8,532	9,083	9,089	9,151	9,214
Supplier expenses	4,232	2,873	2,714	2,737	2,747
Grants expenses	1,500	1,500	1,500	1,500	-
Depreciation and amortisation	242	267	272	152	121
Total expenses	14,506	13,723	13,575	13,540	12,082
LESS:					
OWN-SOURCE INCOME					
Revenue					
Other revenue	2,265	2,232	2,071	2,079	586
Total revenue	2,265	2,232	2,071	2,079	586
Gains					
Other	138	136	135	136	137
Total gains	138	136	135	136	137
Total own-source income	2,403	2,368	2,206	2,215	723
Net cost of (contribution by) services	12,103	11,355	11,369	11,325	11,359
Revenue from Government	11,110	11,088	11,097	11,173	11,238
Surplus (deficit)	(993)	(267)	(272)	(152)	(121)
Surplus (deficit) attributable to the Australian Government	(993)	(267)	(272)	(152)	(121)
OTHER COMPREHENSIVE INCOME					
Changes in asset revaluation reserves	-	-	-	-	-
Total other comprehensive income	-	-	-	-	-
Total comprehensive income (loss) attributable to the Australian Government	(993)	(267)	(272)	(152)	(121)
Note: Reconciliation of comprehensive income attributable to the agency					
	2017-18 \$'000	2018-19 \$'000	2019-20 \$'000	2020-21 \$'000	2021-22 \$'000
Total comprehensive income (loss) attributable to the Australian Government	(993)	(267)	(272)	(152)	(121)
plus non-appropriated expenses					
depreciation and amortisation expenses	242	267	272	152	121
Total comprehensive income (loss) attributable to the agency	(751)	-	-	-	-

Table 3.2: Budgeted Departmental Balance Sheet (as at 30 June)

	2017-18 Estimated actual \$'000	2018-19 Budget \$'000	2019-20 Forward estimate \$'000	2020-21 Forward estimate \$'000	2021-22 Forward estimate \$'000
ASSETS					
Financial assets					
Cash and cash equivalents	110	110	110	110	110
Receivables	3,653	3,590	3,500	3,498	3,488
Total financial assets	3,763	3,700	3,610	3,608	3,598
Non-financial assets					
Buildings	-	-	-	-	-
Property, plant and equipment	338	262	178	110	83
Intangibles	33	26	9	11	11
Other	67	67	67	67	67
Total non-financial assets	438	355	254	188	161
Total assets	4,201	4,055	3,864	3,796	3,759
LIABILITIES					
Payables					
Suppliers	410	410	410	410	410
Other payables	258	258	258	258	258
Total payables	668	668	668	668	668
Provisions					
Employees	1,995	2,035	2,035	2,035	2,035
Other provisions	189	189	189	189	189
Total provisions	2,184	2,224	2,224	2,224	2,224
Total liabilities	2,852	2,892	2,892	2,892	2,892
Net Assets	1,349	1,163	972	904	867
EQUITY					
Contributed equity	1,230	1,311	1,392	1,476	1,560
Reserves	-	-	-	-	-
Retained surpluses or (accumulated deficits)	119	(148)	(420)	(572)	(693)
Total equity	1,349	1,163	972	904	867

Table 3.3: Departmental Statement of Changes in Equity – Summary of Movement (Budget year 2018-19)

	Retained earnings	Asset revaluation reserve	Contributed equity/ capital	Total equity
	\$'000	\$'000	\$'000	\$'000
Opening balance as at 1 July 2018				
Balance carried forward from previous period	119	-	1,230	1,349
Surplus (deficit) for the period	(267)	-	-	(267)
Capital budget - Bill 1 (DCB)	-	-	81	81
Other movements	-	-	-	-
Estimated closing balance as at 30 June 2019	(148)	-	1,311	1,163

DCB = Departmental Capital Budget.

Table 3.4: Budgeted Departmental Statement of Cash Flows (for the period ended 30 June)

	2017-18 Estimated actual \$'000	2018-19 Budget \$'000	2019-20 Forward estimate \$'000	2020-21 Forward estimate \$'000	2021-22 Forward estimate \$'000
OPERATING ACTIVITIES					
Cash received					
Appropriations	12,243	11,473	11,469	11,457	11,480
GST	282	282	282	282	232
Other cash received	2,224	2,192	2,071	2,079	586
Total cash received	14,749	13,947	13,822	13,818	12,298
Cash used					
Employees	8,492	9,043	9,089	9,151	9,214
Suppliers	4,376	3,019	2,861	2,883	2,842
Grants	1,500	1,500	1,500	1,500	-
GST	282	282	282	282	232
Total cash used	14,650	13,844	13,732	13,816	12,288
Net cash from (or used by) operating activities	99	103	90	2	10
INVESTING ACTIVITIES					
Cash used					
Purchase of property, plant and equipment	180	184	171	86	94
Total cash used	180	184	171	86	94
Net cash from (or used by) investing activities	(180)	(184)	(171)	(86)	(94)
FINANCING ACTIVITIES					
Cash received					
Capital budget - Bill 1 (DCB)	81	81	81	84	84
Total cash received	81	81	81	84	84
Net cash from (or used by) financing activities	81	81	81	84	84
Net increase (or decrease) in cash held	-	-	-	-	-
Cash and cash equivalents at the beginning of the reporting period	110	110	110	110	110
Cash and cash equivalents at the end of the reporting period	110	110	110	110	110

DCB = Departmental Capital Budget.

Table 3.5: Departmental Capital Budget Statement (for the period ended 30 June)

	2017-18 Estimated actual \$'000	2018-19 Budget \$'000	2019-20 Forward estimate \$'000	2020-21 Forward estimate \$'000	2021-22 Forward estimate \$'000
CAPITAL APPROPRIATIONS					
Capital budget - Bill 1 (DCB)	81	81	81	84	84
Total capital appropriations	81	81	81	84	84
Total new capital appropriations represented by:					
Purchase of non-financial assets	81	81	81	84	84
Total represented by	81	81	81	84	84
PURCHASE OF NON-FINANCIAL ASSETS					
Funded by capital appropriation - DCB ^(a)	81	81	81	84	84
Funded internally from departmental resources	99	103	90	2	10
Total acquisitions of non-financial assets	180	184	171	86	94
RECONCILIATION OF CASH USED TO ACQUIRE ASSETS TO ASSET MOVEMENT TABLE					
Total purchases	180	184	171	86	94
Total cash used to acquire assets	180	184	171	86	94

^(a) Does not include annual finance lease costs. Includes purchases from current and previous years' Departmental Capital Budgets (DCB).

Table 3.6: Statement of Asset Movements (Budget year 2018-19)

	Buildings	Other property, plant and equipment	Intangibles	Total
	\$'000	\$'000	\$'000	\$'000
As at 1 July 2018				
Gross book value	-	1,295	593	1,888
Accumulated depreciation/ amortisation and impairment	-	(957)	(560)	(1,517)
Opening net book balance	-	338	33	371
CAPITAL ASSET ADDITIONS				
Estimated expenditure on new or replacement assets				
By purchase - appropriation ordinary annual services	-	164	20	184
Total additions	-	164	20	184
Other movements				
Depreciation/amortisation expense	-	(240)	(27)	(267)
Total other movements	-	(240)	(27)	(267)
As at 30 June 2019				
Gross book value	-	1,459	613	2,072
Accumulated depreciation/ amortisation and impairment	-	(1,197)	(587)	(1,784)
Closing net book balance	-	262	26	288

Table 3.7: Schedule of Budgeted Income and Expenses Administered on Behalf of Government (for the period ended 30 June)

	2017-18 Estimated actual \$'000	2018-19 Budget \$'000	2019-20 Forward estimate \$'000	2020-21 Forward estimate \$'000	2021-22 Forward estimate \$'000
EXPENSES ADMINISTERED ON BEHALF OF GOVERNMENT					
Grants	16,382	16,737	16,864	17,013	17,251
Suppliers	2,297	3,065	3,082	1,368	1,152
Total expenses administered on behalf of Government	18,679	19,802	19,946	18,381	18,403

Table 3.8: Schedule of Budgeted Assets and Liabilities Administered on Behalf of Government (as at 30 June)

	2017-18 Estimated actual \$'000	2018-19 Budget \$'000	2019-20 Forward estimate \$'000	2020-21 Forward estimate \$'000	2021-22 Forward estimate \$'000
ASSETS ADMINISTERED ON BEHALF OF GOVERNMENT					
Financial assets					
Cash and cash equivalents	30	30	30	30	30
Receivables	119	119	119	119	119
Other financial assets	101	101	101	101	101
Total financial assets	250	250	250	250	250
Total assets administered on behalf of Government	250	250	250	250	250
LIABILITIES ADMINISTERED ON BEHALF OF GOVERNMENT					
Payables					
Suppliers	180	180	180	180	180
Grants	70	70	70	70	70
Other payables	-	-	-	-	-
Total payables	250	250	250	250	250
Total liabilities administered on behalf of Government	250	250	250	250	250

Table 3.9: Schedule of Budgeted Administered Cash Flows (for the period ended 30 June)

	2017-18 Estimated actual \$'000	2018-19 Budget \$'000	2019-20 Forward estimate \$'000	2020-21 Forward estimate \$'000	2021-22 Forward estimate \$'000
OPERATING ACTIVITIES					
Cash received					
GST	707	707	707	707	707
Total cash received	707	707	707	707	707
Cash used					
Grant payments	16,382	16,737	16,864	17,013	17,251
Suppliers	2,297	3,065	3,082	1,368	1,152
GST	707	707	707	707	707
Total cash used	19,386	20,509	20,653	19,088	19,110
Net cash from (or used by) operating activities	(18,679)	(19,802)	(19,946)	(18,381)	(18,403)
Net increase (or decrease) in cash held	(18,679)	(19,802)	(19,946)	(18,381)	(18,403)
Cash at beginning of reporting period	30	30	30	30	30
Cash from Official Public Account for:					
- appropriations	18,679	19,802	19,946	18,381	18,403
- GST	707	707	707	707	707
Cash to the Official Public Account - return of GST	(707)	(707)	(707)	(707)	(707)
Cash at end of reporting period	30	30	30	30	30